Although elevated blood glucose is associated with adverse maternal and fetal health outcomes, evidence suggests that women with diabetes may not be receiving comprehensive reproductive health care, including family planning and preconception care. Using a populationbased sample, we evaluated the relationship between contraceptive use and biomarker-identified diabetes.
INTRODUCTION
A growing population of women have diabetes during their reproductive years. 1 Approximately 35% of newly diagnosed cases of diabetes occur between the ages of 18 and 50, and an estimated 19% of women of reproductive age are not normoglycemic. 2, 3 They need reproductive care, tailored to their childbearing goals, that minimizes the harmful impact of elevated blood glucose during pregnancy. During pregnancy, elevated blood glucose secondary to poorly managed diabetes can lead to fetal malformation, pregnancy loss, preterm birth, preeclampsia, macrosomia, and fetal programming that increases the infant's risk of obesity and diabetes later in life. [4] [5] [6] [7] Currently, the American Diabetes Association (ADA) recommends that women with diabetes use contraception while engaging in preconception care to lower glycated hemoglobin (A1C) below 6.5% before pregnancy. 8 However, as a patient population, women with diagnosed diabetes inconsistently receive contraception counseling, use contraception, plan pregnancies, or obtain preconception care, a finding that may be confounded by socioeconomic status or body weight. [9] [10] [11] [12] [13] [14] [15] Using contraception to time pregnancies during periods of better glycemic control can help women with diabetes achieve their childbearing goals while reducing adverse pregnancy outcomes. The patterns of contraceptive use among women whose diabetes is undiagnosed or poorly managed have not been described using nationally representative data. Thus, the objectives of this study were to estimate the relationship between contraceptive use and key measures of glucose dysregulation, including prediabetes, undiagnosed diabetes, diagnosed diabetes, and suboptimal preconception glycemic control, among women of reproductive age in a US national sample. We hypothesized that women with diabetes would be less likely to use contraception than their normoglycemic peers, controlling for demographic characteristics and body mass index (BMI).
METHODS

Data Set and Sample
We used data from the 2007 to 2009 Wave IV of the National Longitudinal Study of Adolescent to Adult Health (Add Health). Ninety-eight percent of participants were interviewed in 2008. Add Health used a stratified, school-based cluster sampling strategy and is representative of US adults who were seventh-to 12th-grade students during the 1994 to 1995 school year. 16 Race and ethnicity were collected from inhome interviews at initial enrollment in 1994 and 1995. All other survey and biological data were collected from the same participants at follow-up home visits from 2007 to 2009. The informed consent process has been described elsewhere. 16 All self-identified nonpregnant female respondents who reported sexual activity with a male partner in the past year were eligible for this analysis. Women were excluded for ✦ Prepregnancy diabetes increases the risk of adverse maternal and fetal health outcomes and is increasingly common in women during their reproductive years.
✦ Women with diabetes are more likely to use no contraception, rather than more effective contraception, than women who are normoglycemic.
✦ Family planning coupled with preconception care to lower blood glucose levels before pregnancy can help women with diabetes achieve their childbearing goals.
missing values, declining to answer or uncertain responses for demographic characteristics (n = 40), BMI (n = 100), contraceptive use (n = 20), or A1C (n = 457). The final, unweighted analytic sample contained 5548 women.
Outcome Measures
The primary outcome was the most effective contraceptive method used in the prior 12 months. Participants were asked to indicate all types of contraceptive use in the prior 12 months and were categorized as using no contraception, less effective contraception, or more effective contraception (Table 1) . Categorization reflects the widely used World Health Organization's model of tiered contraceptive effectiveness. 17 Using the wording from the survey, we defined more effective methods as including tubal ligation/sterilization; vasectomy; intrauterine device (IUD), coil, loop; emergency IUD insertion; Norplant; birth control pills; patch (Ortho Evra); ring (NuvaRing); and shot (Depo-Provera). Less effective methods included condoms (rubbers); female condom; diaphragm, cap or shield; natural family planning (safe periods by temperature, cervical mucus test); rhythm or safe period by calendar; emergency contraception or morning after pill; withdrawal (pulling out); vaginal sponge; contraceptive film; and spermicide foam, jelly, creme, suppositories. For our analyses, women were categorized by the most effective method reported (ie, a pill and condom user would be categorized as more effective method user). We conducted a sensitivity analysis about the categorization of 10 women who indicated they used other methods.
Diabetes Status
Diabetes status was the primary predictor. Capillary whole blood was collected from a finger stick and analyzed to determine A1C; the high reliability and validity of this measure have been documented elsewhere. 18, 19 Women were categorized as having diabetes if they had 1) an A1C greater than or equal to 6.5%, 2) self-reported diabetes diagnosis (an affirmative answer when asked if they had a "history of being told by a doctor or health care professional that you have diabetes (if female, outside of pregnancy)", or 3) documentation of antihyperglycemic medication use in a prescription inventory of the previous 4 weeks. Women were categorized as having prediabetes if their A1C was between 5.7% and 6.4% without a history of a diabetes diagnosis or antihyperglycemic medication use. Women were categorized as normoglycemic if they had no evidence of prediabetes or diabetes. These criteria reflected ADA clinical practice guidelines and are described elsewhere. 19 Type 1 diabetes mellitus and type 2 diabetes mellitus were not distinguishable in this survey.
Additionally, all women with diabetes were categorized by diagnosis status and glycemic control. First, women with diabetes were categorized as diagnosed if they had a selfreported diabetes diagnosis or took antihyperglycemic medications, and undiagnosed if they had neither. Second, women with diabetes were categorized as having suboptimal preconception glycemic control or not. Suboptimal preconception glycemic control was operationalized as A1C greater than or equal to 6.5% based on the ADA's recommended glycemic targets before pregnancy. Although the ADA considers 7% to be an appropriate goal for many adults who are not pregnant, we use the ADA's more conservative criterion for the preconception period. 8 By this definition, all undiagnosed women in the sample have A1C greater than or equal to 6.5%. Some women with diagnosed diabetes had an A1C greater than or equal to 6.5%, whereas some had A1C less than 6.5%, likely because of treatment and lifestyle changes.
Covariates
Analytic models controlled for characteristics that have been linked to diabetes risk and contraceptive behavior: demographic characteristics (race and ethnicity, insurance type, limited access to health care in the prior 12 months, and educational attainment) and BMI, with height and weight measured by field interviewers. 12, [20] [21] [22] [23] Educational attainment was a proxy for socioeconomic position relevant to health status because, in this age range, educational attainment is typically more stable than income. 24 We also conducted a sensitivity analysis in which we included age in the model.
Data Analysis
We used STATA version 14.1 (StataCorp LLC, College Station, TX) with SVY and SUBPOP commands to conduct designbased analyses that accounted for stratification, clustering, and unequal probability of selection. 25 Application of the survey weights produced unbiased weighted population estimates of diabetes prevalence and contraceptive use. We used Taylor series linearization to perform design-based standard error computations. Associations were tested with the second order Rao-Scott design-adjusted F test, with null hypotheses of independence. We modeled diabetes status as a predictor of contraceptive use with pseudo maximum-likelihood multinomial logit regression. We exponentiated beta coefficients to produce adjusted odds ratios (aORs) with 95% CIs. The overall significance of each predictor was examined with an adjusted Wald test. In order to model diagnosis status and suboptimal preconception glycemic control as predictors of contraceptive use, we conducted an additional unconditional domain analysis of women with diabetes. All models adjusted for demographic characteristics and BMI. All tests were 2-tailed, with a .05 significance level. Institutional review board approval was obtained from the University of North Carolina at Chapel Hill.
RESULTS
Diabetes Status and Contraceptive Use
Most sexually active, nonpregnant women aged 24 to 32 years used contraception in the prior year ( Table 2 ). The effectiveness of contraception used had significant bivariate associations with demographic variables, BMI, and diabetes status (all P Ͻ .001). We estimated that 20.8% of the population had prediabetes and that 5.9% had diabetes. More women with diabetes used less effective contraception (33.6% vs 25.2%) or no contraception (28.8% vs 16.4%) than their normoglycemic peers (P Ͻ .001).
In the multinomial analysis, compared with women with normoglycemia, women with diabetes had greater adjusted odds of using no contraception (aOR 1.90; 95% CI, 1.25-2.87) than more effective contraception (Table 3 ). There were not significant differences between use of less effective and more effective methods by women with diabetes compared with women with normoglycemia. Contraceptive use did not differ between women with prediabetes and normoglycemia.
Demographic characteristics and BMI were significant predictors (Table 3 ). Using no contraception was less likely among non-Hispanic black women but more likely among women with less education or who were obese than their respective referents. Use of less effective contraception, rather than more effective contraception, was more likely among non-Hispanic black women, Hispanic women, less educated women, women without insurance, and women without access to health care than their respective referents.
Sensitivity Analyses
We conducted a sensitivity analysis, categorizing the women who reported using other methods as more effective, less effective, or excluded from the analysis. We saw minor changes in coefficients and no changes in statistical significance. We report the analysis excluding those who reported other methods. We also examined the addition of age as a covariate; age did not change the statistical significance of other variables or the estimates in any meaningful way.
Variation in Contraceptive Use Among Women with Diabetes
Among the 381 women with diabetes, 60.6% were diagnosed (n = 213), and 56.0% had suboptimal preconception glycemic control indicated by A1C greater than or equal to 6.5% (n = 241). Among women with diabetes whose A1C was greater than or equal to 6.5%, 70.4% were undiagnosed and 29.6% were diagnosed.
Contraceptive use was significantly associated with diagnosis status (P Ͻ .001; Table 4 ). Over half of undiagnosed women used less effective contraception (51.1%); using no contraception and more effective contraception were both more common among diagnosed than undiagnosed women with diabetes. In an adjusted multinomial model (Table 5) , the association remained, indicating that undiagnosed women had greater odds of using less effective contraceptive, rather than more effective contraception, compared with diagnosed women (aOR 3.39, 95% CI, 1.44-7.96). Table 4 also indicates a similar significant association between suboptimal preconception glycemic control and contraceptive use among women with diabetes (P Ͻ .001). Nearly half of the women with A1C greater than or equal to 6.5% used less effective contraception (45.4%). In the adjusted model (Table 6) , the association between glycemic control and contraceptive use remained significant because women with A1C greater than or equal to 6.5% had significantly lower odds of using no contraception than less effective contraception compared with women with A1C below 6.5% (aOR 0.31; 95% CI, 0.13-0.74; P = .009; not shown). The step-down tests comparing no or less effective with more effective contraception were not significant. As seen in Tables 5 and 6 , Hispanic women with diabetes were more likely to use less effective contraception and less likely to use no contraception than non-Hispanic white women with diabetes. Obese women with diabetes were more likely to use no contraception than normal or underweight women with diabetes.
DISCUSSION
To our knowledge, this is the first study to use a populationbased sample to describe contraceptive use among women with biomarker-identified diabetes. Although the majority of women with normoglycemia used more effective contraception, most women with diabetes were using either less effective contraception or no contraception. Our data supported the hypothesis that women with diabetes had higher odds of using no method, rather than a more effective method, in comparison with women with normoglycemia.
Our findings add to the available evidence about contraceptive use by women with diabetes, which has largely described only women who are diagnosed. Two previous studies found no differences in the odds of contraception nonuse by women with diagnosed diabetes compared with normoglycemic women. 12, 13 In contrast, we found that women with diabetes had significantly greater adjusted odds of not using contraception when we aggregated women with diagnosed diabetes and undiagnosed diabetes.
Clinical Implications
Midwives and other women's health care providers should be prepared to provide patient-centered care to sexually active women with diabetes who are not using contraception. Patients who could become pregnant deserve clear information about the possibility of complications and means to reduce risks from health care providers who respect their reproductive autonomy. Concerns about the inadequate provision of diabetes-specific preconception care have been voiced 9, 26, 27 and are lent weight by our finding that nearly 20% of women with an A1C greater than or equal to 6.5% were using no contraception.
Because many women in this age cohort are unaware of their diabetes status or glycemic control, 1 our findings support structuring preconception care to be universal and routine in primary care, including midwifery practice. [27] [28] [29] High rates of undiagnosed diabetes among young adult women drive home the importance of adhering to the ADA's diabetes screening criteria for health care providers serving this patient population. 1 Because achieving and then sustaining glycemic control requires constant maintenance, preventing unintended pregnancies while A1C is greater than or equal to 6.5% also requires undisrupted access to primary care without financial or institutional barriers. Policies should support access to quality care that addresses both family planning and diabetes management needs.
According to the Centers for Disease Control and Prevention's Medical Eligibility Criteria for Contraceptive Use, women with diabetes may typically use the contraceptive method of their choice (with the exception that women who have had diabetes for more than 20 years or have vascular damage may be contraindicated from using Depo-Provera or combined hormonal contraceptives). 30 In Add Health, most women with diabetes used less effective contraception, which may be preferable to women who desire methods that are generally less expensive, available without a prescription or health care interaction, nonhormonal, or prevent transmission of sexually transmitted infections. 31 Respecting women's preferences about contraception features is essential for preventing reproductive coercion. It is also critical for health care providers and researchers to identify and dismantle barriers encountered by women with diabetes who are using less effective contraception but desire more effective methods.
Our findings offer population estimates of women who need diabetes-specific reproductive health care, including care that both prevents and prepares for pregnancy in the context of diabetes management. In our discussion, we highlight the women who are using no contraception or less effective methods, as they more likely to become pregnant than women who are using more effective methods. 32 However, we do not quantify unmet contraceptive need because Add Health only queries women's pregnancy intentions retrospectively after pregnancies are reported. Prospective pregnancy attitudes at the time of data collection were not collected. In the general population, 4.5% of women aged 15 to 44 years are not using contraception because they are seeking pregnancy, so it is reasonable to assume an unknown proportion of contraception nonusers in this sample are as well. 33 In the future, the unmet contraceptive need could be discerned by data collection that includes concurrent determination of pregnancy intentions, current contraceptive use, and A1C.
Having the full spectrum of reproductive health services available may be particularly important for women with diabetes because data suggest that diabetes can complicate pregnancy intentions. Some women with diabetes report feeling ambivalence about childbearing because they feel both desire for pregnancy and fear of diabetes-associated risks. 34 Women reported that guilt about diabetes harming their offspring delayed their plans for pregnancy 35 or made it hard for them to think about planning. 36 Women may perceive diabetes to reduce their fertility, which some women find distressing and can make preconception care, including contraception, seem irrelevant. [37] [38] [39] Additionally, women with diabetes have reported great happiness about unintended pregnancies. 38 More research is needed to understand how women want family planning and preconception care incorporated into diabetes management. Future research should continue to build on the emerging evidence that the postpartum period may be a particularly promising time for innovations in family planning service delivery. 40 We noted 2 other trends in our data. In every model, obese women were more likely to use no contraception rather than more effective contraception, and Hispanic women were more likely to use less effective rather than more effective contraception. Women from the groups most affected should be invited to be collaborators, providing insight about how they understand the myriad factors that influence their contraceptive choices and input about the acceptability of interventions to address any unmet contraceptive need.
Limitations
We note several limitations. Our analysis being crosssectional, we do not suggest that diabetes motivates contraceptive use; rather, we are describing the observable patterns of contraceptive use among women with diabetes. Unfortunately, our description cannot distinguish type 1 diabetes mellitus and type 2 diabetes mellitus, but our findings are still meaningful because elevated blood glucose endangers pregnancies of women with both kinds of prepregnancy diabetes. 8 The generalizability of our findings is limited because some contraceptive methods listed in Add Health are no longer on the market in the United States, and new forms of the contraceptive implant (eg, Implanon, Nexplanon) have become available since data were collected. Add Health did not contain data about how long participants used each method, whether multiple methods were used concurrently or consecutively, or satisfaction with the method; those dimensions should be explored in future research.
Since these data were collected between 2007 and 2009, guidelines around the long-acting reversible contraceptives 42 We felt comfortable using Add Health data from 2007 to 2009 because the significant changes in the less effective method category between 2008 and 2014 were smaller (2.9 percentage point increase in use of withdrawal and 1.0 percentage point increase in use of natural family planning) and no changes were seen in the percentage of women at risk of unintended pregnancy who used no method, despite the ACA ostensibly making all prescription contraceptives more accessible. 42 Despite its limitations, we determined that Add Health is more suitable for addressing our hypotheses than other population data sets. In particular, the NSFG could not be used to address our hypotheses because diabetes status is not determined by biomarker. The National Health and Nutrition Examination Survey, the population-based sample frequently used to generate population estimates about biomarker-identified diabetes, has few contraceptive questions and a smaller number of young adults than Add Health. Because diabetes is increasingly common among women of reproductive age, data should be collected to update these findings. Until then, this is the best estimate that is available of family planning behaviors of young adult women with diagnosed and undiagnosed diabetes in the United States. Women with diabetes in young adulthood are using more effective contraception less than their normoglycemic peers. Evaluating and improving family planning for women with current or potential glucose dysregulation is critical for helping women achieve reproductive goals while minimizing the risks associated with elevated blood glucose during pregnancy.
